Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Tiedt R, King FJ, Stamm C, Niederst MJ, Delach S, Zumstein-Mecker S, Meltzer J, Mulford IJ, Labrot E, Engstler BS, Baltschukat S, Kerr G, Golji J, Wyss D, Schnell C, Ainscow E, Engelman JA, Sellers WR, Barretina J, Caponigro G, Porta DG.
Tiedt R, et al. Among authors: meltzer j.
Cell Rep. 2023 Apr 25;42(4):112297. doi: 10.1016/j.celrep.2023.112297. Epub 2023 Mar 23.
Cell Rep. 2023.
PMID: 36961816
Free article.